Publication | Closed Access
Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine
146
Citations
14
References
2015
Year
IDeg has a longer half-life (> 25 h) than IGlar. Exposure and glucose-lowering effects are more stable and evenly distributed across one dosing interval for IDeg versus IGlar (Clinical trials.gov identifier: NCT01114542).
| Year | Citations | |
|---|---|---|
Page 1
Page 1